MDxHealth provides actionable molecular diagnostic information to personalise the diagnosis and treatment of cancer. Our tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies to assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, and prediction of response to a specific therapy.
Epigenetics is an exciting area of molecular biology that identifies key changes in gene activity that do not involve changes to the underlying genetic code. Epigenetic "markers" tell genes to switch on or off, to speak loudly or whisper. It is through these epigenetic markers that environmental factors like diet, stress and prenatal nutrition can make an imprint on genes (DNA methylation) that are passed from one generation to the next. Some of these DNA methylation imprints can turn a healthy cell into a cancer cell.
We believe that our proprietary, accurate and scalable epigenetic technologies provide a key competitive advantage in the diagnosis, prognosis and management of cancer. In addition to our ongoing and planned studies for our tests to assess the risk of prostate cancer (ConfirmMDx and SelectMDx) and bladder cancer (AssureMDx), our product pipeline includes tests for kidney and other urologic cancers.